AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer
15 Julio 2024 - 7:00AM
Business Wire
AffyImmune, a clinical-stage biotechnology company committed to
developing novel, first-in-class CAR T cell therapies, today
announced the appointment of Daniel Janse, Ph.D. as President and
Chief Executive Officer. Dr. Janse brings twenty years of expertise
and an extensive background in biopharmaceutical research and
development, operations, and leadership to drive the company
forward.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240715681945/en/
Dr. Daniel Janse, CEO, AffyImmune (Photo
credit: AffyImmune)
“We are thrilled to welcome Dr. Janse as the new CEO of
AffyImmune,” said Simone Song, Founding Partner, ORI Capital and
Board Director at AffyImmune. “His extensive experience in the
biotech industry and his proven leadership in driving innovation
and strategic growth make him the ideal executive to lead
AffyImmune into its next phase of growth. We have full confidence
in his ability to advance our mission of bringing CAR T cell
therapies to patients with solid tumors.”
Dr. Janse joins AffyImmune from Northpond Ventures, where he
served as Managing Director. He was a board member at several
biotechnology companies, including Garuda Therapeutics, Triumvira
Immunologics, Walking Fish Therapeutics, Artisan Bio, Aro
Biotherapeutics, EnPlusOne Biosciences, and Isolere Bio.
Previously, he was the Chief Operating Officer and Chief Business
Officer at Arbor Biotechnologies, where he led scientific and
general operations, business development, program and alliance
management, and corporate development and strategy.
His career also includes leadership positions at Juno
Therapeutics, Johnson & Johnson Innovation Center, Inventages
Venture Capital, and McKinsey & Company. Dr. Janse was a
Presidential Postdoctoral Fellow at Novartis Institutes for
Biomedical Research. He holds a Ph.D. from Harvard University,
where he trained in the laboratory of Dr. George Church in the
Department of Genetics.
“I am honored to join AffyImmune at such a pivotal time in the
company’s journey,” said Dr. Daniel Janse, Chief Executive Officer,
AffyImmune. “I look forward to working with the team and Board of
Directors to continue and expedite the development of AIC100 for
patients with advanced thyroid cancers and non-small-cell lung
cancer. The unique ability for AffyImmune to target ICAM-1 using an
affinity-tuned LFA-1 binder and to track AIC100 after
administration to patients are exciting scientific breakthroughs
that can transform the sector.”
At the ASCO 2024 meeting, AffyImmune announced a confirmed
complete response in a patient from its Phase 1 study evaluating
the safety and efficacy of AIC100, an ICAM-1 targeting and
affinity-tuned LFA-1 binder CAR T-cell therapy in advanced thyroid
cancer. A metabolic complete response (mCR) was achieved in one
patient with anaplastic thyroid cancer, the most aggressive form of
the disease. AffyImmune is the first to demonstrate the potential
of single-dose, single-agent autologous CAR T to induce a complete
response in a patient with a solid tumor.
About AffyImmune Therapeutics
AffyImmune is a clinical-stage biopharmaceutical company
committed to developing a first-in-class, ICAM-1 targeting and
affinity-tuned LFA-1 binder CAR T therapy to transform the lives of
patients with advanced solid cancers. The Company’s proprietary
technology utilizing ICAM-1/LFA-1 interaction can potentially
address the critical CAR T challenges such as toxicity, antigen
loss, T-cell trafficking and exhaustion, while also allowing in
vivo tracking of the CAR T cells. Its lead candidate, AIC100, is
currently in a Phase 1 study to treat patients with advanced
thyroid cancers including advanced differentiated thyroid cancer
(ADTC) and anaplastic thyroid cancer (ATC). AffyImmune is
developing a focused pipeline in ICAM-1-positive cancers with high
unmet medical need. AffyImmune is based in Natick, Massachusetts.
For more information, visit www.affyimmune.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715681945/en/
Media: Kimberly Ha KKH Advisors
kimberly.ha@kkhadvisors.com 917-291-5744